Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome

Conditions:   Acute Lymphoblastic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia;   Acute Myeloid Leukemia in Remission;   Hematopoietic Cell Transplantation Recipient;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Secondary Acute Myeloid  Leukemia Interventions:   Drug: Fludarabine;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Radiation: Total Marrow Irradiation Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials